

SAKK presentations at ESMO 2024

SAKK trials

Trial: SAKK 41/13

Title: Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients – The Phase III, Prospective-Randomized Placebo-Controlled Multicenter SAKK 41/13 Trial

Speaker: Ulrich Güller

Type of presentation: Proffered paper presentation

Number: 512O

Date and time: Sunday 15. September 2024, 08:40 - 08:50

Session name: Proffered paper session 1: GI tumours, lower (ID 116)

Place: Sevilla Auditorium - Hall 2

Trial: SAKK 15/19

Title: Thoracic radiotherapy plus maintenance Durvalumab after first line Carboplatin and Etoposide plus Durvalumab in extensive-stage disease small cell lung cancer (ED-SCLC) – a multicenter single arm open label phase II trial (SAKK 15/19)

Speaker: Alfredo Addeo

Type of presentation: Poster

Number: 1791P

Date and time: Saturday, 14. September 2024, 12:00-13:00

Trial: SAKK 16/96, 16/00, 16/01, 16/08 and 16/14

Title: Sex specific efficacy and safety outcomes in operable Stage III Non-Small Cell Lung Cancer (NSCLC): pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14

Speaker: Lorenz Frehner

Type of presentation: Poster

Number: 1223P

Date and time: Saturday, 14. September 2024, 12:00-13:00

Trial: SAKK 21/18 (meta-analysis)

Title: Cardiovascular events related to CDK4/6 inhibitors: a systematic review and safety meta-analysis of randomized controlled trials

Speaker: Louis Boismoreau

Type of presentation: Poster

Number: 334P

Date and time: Monday, 16. September 2024, 12:00-13:00

Intergroup

Trial: STAMPEDE

Title: Adding metformin to androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC): Overall survival (OS) results from the multi-arm, multi-stage randomised platform trial STAMPEDE

Speaker: Silke Gillessen

Type of presentation: Mini oral presentation

Number: LBA70

Date and time: Monday 16. September 2024, 10:15 - 11:45

Session name: Mini oral session: GU tumours, prostate (ID 18)

Place: Madrid Auditorium - Hall 2